#United States #Cambridge #Flare Therapeutics #Douglas Manion #Daphne Karydas

Flare Therapeutics: Upcoming December Conferences Overview

Flare Therapeutics Inc. is making headlines this December as the clinical-stage biotechnology company prepares to present at two significant investor conferences. With a mission to discover precision medicines targeting transcription factors, Flare Therapeutics is at the forefront of advancing therapeutic strategies for oncology and beyond.

Conference Details

The calendar is set for December 4 and December 5, 2024, when Flare Therapeutics executives will discuss the company's innovative work and future prospects. The first event is the 7th Annual Evercore ISI HealthCONx Conference, taking place in Coral Gables, Florida. Douglas Manion, M.D., FRCP (C), the Chief Executive Officer, and Daphne Karydas, the President and Chief Financial Officer, will engage in a fireside chat at 12:55 p.m. ET. This discussion is expected to delve into the challenges and opportunities within the biotechnology landscape, particularly about Flare’s unique approach to drug development.

The following day, December 5, Flare Therapeutics will feature at the Piper Sandler 36th Annual Healthcare Conference in New York City. Dr. Douglas Manion will present a comprehensive overview of the company's missions and objectives at 9:50 a.m. ET, outlining their innovative strategies in the oncology space. Furthermore, Daphne Karydas will hold meetings with investors, offering insights into Flare's financial and operational directions, which could attract significant interest.

About Flare Therapeutics

Founded with a focus on making transcription factors druggable, Flare Therapeutics employs a unique integrated discovery engine, which seamlessly merges genetic and biochemical insights to identify potential pharmaceuticals. Their proprietary library of electrophilic compounds supports a promising proteomic and mass spectrometry platform, propelling Flare into a leadership position within the biotechnology sector.

Through its unwavering commitment, the company has rapidly cultivated an impressive pipeline, notably featuring FX-909. This first-in-class investigational orally bioavailable small molecule inhibitor targets PPARG, a crucial regulator implicated in advanced urothelial cancer, currently undergoing Phase I trials. The company is also advancing another promising program aimed at prostate cancer, which is entering the Investigational New Drug (IND)-enabling phase. These advancements signify Flare's dedication and capability in addressing significant unmet medical needs in oncology.

Flare Therapeutics is not merely focused on the present; it is ambitiously targeting transcription factors involved in various therapeutic areas. The company’s innovation is a testament to its vision of fully unlocking the potential of transcription factor modulation, which has traditionally been considered elusive.

With the December conferences approaching, industry watchers are keen to learn more about Flare’s strategic insights and pipeline developments. Such opportunities to engage directly with executives are invaluable, as they offer deeper understandings of the biotechnology market's landscape.

Conclusion

As Flare Therapeutics gears up for these significant events, there is a palpable excitement surrounding their initiatives. This December, the presentations are expected not only to highlight Flare's achievements but also to pave the way for future collaborations and investments crucial for advancing their cutting-edge therapies. Stakeholders and interested parties are encouraged to stay tuned as Flare Therapeutics showcases its commitment to innovate within the healthcare sector.

For more updates and information on Flare Therapeutics, visit www.flaretx.com and follow them on LinkedIn for latest announcements.